A synthetic peptide vaccine which protects dogs against challenge with virulent canine parvovirus is described. The amino acid sequence used was discovered in previous studies on the immunogenic properties of previously mapped antigenic sites and represents the amino-terminal region of viral protein VP2. As with marker vaccines, it is possible to discriminate between vaccinated dogs that have not been exposed to the virus and dogs that have been infected with the virus. The protective mechanism can be explained by a humoral response against the peptide aided by T-cell epitopes contained in the carrier protein used for peptide coupling. This is the first example of a synthetic peptide vaccine that induces protection in target animals.

, , , , , , , , , , , , , , , , , , , , , ,
Journal of Virology
Erasmus MC: University Medical Center Rotterdam

Langeveld, J. P. M., Casal, J. I., Osterhaus, A., Cortes, E., de Swart, R., Vela, C., … Meloen, R. H. (1994). First peptide vaccine providing protection against viral infection in the target animal: studies of canine parvovirus in dogs. Journal of Virology, 68, 4506–4513. Retrieved from http://hdl.handle.net/1765/3499